Venous Thromboembolic Disease in the Intensive Care Unit

ABSTRACT

Critically ill patients are at increased risk of developing venous thromboemboli (VTE). Risk factors that predispose them to acquiring VTE encompass factors that usually afflict the general medical population as well as factors attained in the intensive care unit (ICU) (e.g., sedation, mechanical ventilation). The poor cardiopulmonary reserve of this patient population is intolerant of even small pulmonary emboli (PE), which emphasizes the importance of preventing VTE from ever occurring. Indeed, the complications associated with hospital-acquired VTE increase morbidity, mortality, hospital length of stay, and costs. Without thromboprophylaxis, the incidence of VTE in the ICU ranges from 15 to 60%. Systematic implementation of VTE prophylaxis significantly reduces this rate and as a consequence, morbidity and mortality. In fact, prevention of VTE is so important that the American College of Chest Physicians (ACCP) developed guidelines on the use of routine VTE prophylaxis in critically ill patients. Therefore, upon admission, all ICU patients should be evaluated for and immediately prescribed the appropriate thromboprophylaxis therapy.

KEYWORDS

Venous thromboembolism - intensive care unit - prevention

REFERENCES

• 1 Cade J F. High risk of the critically ill for venous thromboembolism.  Crit Care Med. 1982;  10 448-450
• 2 Fraisse F, Holzapfel L, Couland J M The Association of Non-University Affiliated Intensive Care Specialist Physicians of France et al. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD.  Am J Respir Crit Care Med. 2000;  161(4 Pt 1) 1109-1114
• 3 Attia J, Ray J G, Cook D J, Douketis J, Ginsberg J S, Geerts W H. Deep vein thrombosis and its prevention in critically ill adults.  Arch Intern Med. 2001;  161 1268-1279
• 4 McCarthy S T, Turner J J, Robertson D, Hawkey C J, Macey D J. Low-dose heparin as a prophylaxis against deep-vein thrombosis after acute stroke.  Lancet. 1977;  2 800-801
• 5 Kelly J, Rudd A, Lewis R, Hunt B J. Venous thromboembolism after acute stroke.  Stroke. 2001;  32 262-267
• 6 McCarthy S T, Turner J. Low-dose subcutaneous heparin in the prevention of deep-vein thrombosis and pulmonary emboli following acute stroke.  Age Ageing. 1986;  15 84-88
• 7 Crowther M A, Cook D J, Griffith L E et al.. Deep venous thrombosis: clinically silent in the intensive care unit.  J Crit Care. 2005;  20 334-340
• 8 Cook D, Crowther M, Meade M et al.. Deep venous thrombosis in medical-surgical critically ill patients: prevalence, incidence, and risk factors.  Crit Care Med. 2005;  33 1565-1571
• 9 Dalen J E. Pulmonary embolism: what have we learned since Virchow? Natural history, pathophysiology, and diagnosis.  Chest. 2002;  122 1440-1456
• 10 Kearon C. Natural history of venous thromboembolism.  Circulation. 2003;  107(23, Suppl 1) I22-I30
• 11 Moser K M, LeMoine J R, Nachtwey F J, Spragg R G. Deep venous thrombosis and pulmonary embolism: frequency in a respiratory intensive care unit.  JAMA. 1981;  246 1422-1424
• 12 Ibrahim E H, Iregui M, Prentice D, Sherman G, Kollef M H, Shannon W. Deep vein thrombosis during prolonged mechanical ventilation despite prophylaxis.  Crit Care Med. 2002;  30 771-774
• 13 Neuhaus A, Bentz R R, Weg J G. Pulmonary embolism in respiratory failure.  Chest. 1978;  73 460-465
• 14 Pingleton S K, Bone R C, Pingleton W W, Ruth W E. Prevention of pulmonary emboli in a respiratory intensive care unit: efficacy of low-dose heparin.  Chest. 1981;  79 647-650
• 15 Cullen D J, Nemeskal A R. The autopsy incidence of acute pulmonary embolism in critically ill surgical patients.  Intensive Care Med. 1986;  12 399-403
• 16 Blosser S A, Zimmerman H E, Stauffer J L. Do autopsies of critically ill patients reveal important findings that were clinically undetected?.  Crit Care Med. 1998;  26 1332-1336
• 17 Geerts W, Cook D, Selby R, Etchells E. Venous thromboembolism and its prevention in critical care.  J Crit Care. 2002;  17 95-104
• 18 Perkins G D, McAuley D F, Davies S, Gao F. Discrepancies between clinical and postmortem diagnoses in critically ill patients: an observational study.  Crit Care. 2003;  7 R129-R132
• 19 Fernandez-Segoviano P, Lázaro A, Esteban A, Rubio J M, Iruretagoyena J R. Autopsy as quality assurance in the intensive care unit.  Crit Care Med. 1988;  16 683-685
• 20 Mort T C, Yeston N S. The relationship of pre mortem diagnoses and post mortem findings in a surgical intensive care unit.  Crit Care Med. 1999;  27 299-303
• 21 Crowther M A, Cook D J, Griffith L E et al.. Neither baseline tests of molecular hypercoagulability nor D-dimer levels predict deep venous thrombosis in critically ill medical-surgical patients.  Intensive Care Med. 2005;  31 48-55
• 22 Spyropoulos A C, Lin J. Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations.  J Manag Care Pharm. 2007;  13 475-486
• 23 Ollendorf D A, Vera-Llonch M, Oster G. Cost of venous thromboembolism following major orthopedic surgery in hospitalized patients.  Am J Health Syst Pharm. 2002;  59 1750-1754
• 24 Patel R, Cook D J, Meade M O Burden of Illness in venous ThromboEmbolism in Critical care (BITEC) Study Investigators et al. Burden of illness in venous thromboembolism in critical care: a multicenter observational study.  J Crit Care. 2005;  20 341-347
• 25 Samama M M, Cohen A T, Darmon J Y Prophylaxis in Medical Patients with Enoxaparin Study Group et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients.  N Engl J Med. 1999;  341 793-800
• 26 Leizorovicz A, Cohen A T, Turpie A G, Olsson C G, Vaitkus P T, Goldhaber S Z. PREVENT Medical Thromboprophylaxis Study Group . Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients.  Circulation. 2004;  110 874-879
• 27 Cohen A T, Davidson B L, Gallus A S et al.. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial.  BMJ. 2006;  332 325-329
• 28 Geerts W H, Bergqvist D, Pineo G F American College of Chest Physicians et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).  Chest. 2008;  133(6, Suppl) 381S-453S
• 29 Kierkegaard A, Norgren L. Graduated compression stockings in the prevention of deep vein thrombosis in patients with acute myocardial infarction.  Eur Heart J. 1993;  14 1365-1368
• 30 Elliott C G, Dudney T M, Egger M et al.. Calf-thigh sequential pneumatic compression compared with plantar venous pneumatic compression to prevent deep-vein thrombosis after non-lower extremity trauma.  J Trauma. 1999;  47 25-32
• 31 Murakami M, McDill T L, Cindrick-Pounds L et al.. Deep venous thrombosis prophylaxis in trauma: improved compliance with a novel miniaturized pneumatic compression device.  J Vasc Surg. 2003;  38 923-927
• 32 Ginzburg E, Cohn S M, Lopez J, Jackowski J, Brown M, Hameed S M. Miami Deep Vein Thrombosis Study Group . Randomized clinical trial of intermittent pneumatic compression and low molecular weight heparin in trauma.  Br J Surg. 2003;  90 1338-1344
• 33 Kurtoglu M, Yanar H, Bilsel Y et al.. Venous thromboembolism prophylaxis after head and spinal trauma: intermittent pneumatic compression devices versus low molecular weight heparin.  World J Surg. 2004;  28 807-811
• 34 Limpus A, Chaboyer W, McDonald E, Thalib L. Mechanical thromboprophylaxis in critically ill patients: a systematic review and meta-analysis.  Am J Crit Care. 2006;  15 402-410 quiz/discussion, 411-412
• 35 Kearon C, Julian J A, Newman T E, Ginsberg J S. Noninvasive diagnosis of deep venous thrombosis. McMaster Diagnostic Imaging Practice Guidelines Initiative.  Ann Intern Med. 1998;  128 663-677
• 36 Douketis J, Cook D, Meade M Canadian Critical Care Trials Group et al. Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study.  Arch Intern Med. 2008;  168 1805-1812
• 37 Dörffler-Melly J, de Jonge E, Pont A C et al.. Bioavailability of subcutaneous low-molecular-weight heparin to patients on vasopressors.  Lancet. 2002;  359 849-850
• 38 Priglinger U, Delle Karth G, Geppert A et al.. Prophylactic anticoagulation with enoxaparin: is the subcutaneous route appropriate in the critically ill?.  Crit Care Med. 2003;  31 1405-1409
• 39 Haas C E, Kaufman D C, Jones C E, Burstein A H, Reiss W. Cytochrome P450 3A4 activity after surgical stress.  Crit Care Med. 2003;  31 1338-1346
• 40 Jochberger S, Mayr V, Luckner G et al.. Antifactor Xa activity in critically ill patients receiving antithrombotic prophylaxis with standard dosages of certoparin: a prospective, clinical study.  Crit Care. 2005;  9 R541-R548
• 41 Rommers M K, Van der Lely N, Egberts T C, van den Bemt P M. Anti-Xa activity after subcutaneous administration of dalteparin in ICU patients with and without subcutaneous oedema: a pilot study.  Crit Care. 2006;  10 R93
• 42 Guyatt G H, Cook D J, Jaeschke R, Pauker S G, Schünemann H J. Grades of recommendation for antithrombotic agents: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).  Chest. 2008;  133(6, Suppl) 123S-131S
• 43 Geerts W H, Jay R M, Code K I et al.. A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma.  N Engl J Med. 1996;  335 701-707
• 44 Shorr A F, Jackson W L, Sherner J H, Moores L K. Differences between low-molecular-weight and unfractionated heparin for venous thromboembolism prevention following ischemic stroke: a metaanalysis.  Chest. 2008;  133 149-155